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Circadian rhythms are daily rhythms that regulate many biological processes – from
gene transcription to behavior – and a disruption of these rhythms can lead to a myriad
of health risks. Circadian rhythms are entrained by light, and their 24-h oscillation
is maintained by a core molecular feedback loop composed of canonical circadian
(“clock”) genes and proteins. Different modulators help to maintain the proper rhythmicity
of these genes and proteins, and one emerging modulator is dopamine. Dopamine
has been shown to have circadian-like activities in the retina, olfactory bulb, striatum,
midbrain, and hypothalamus, where it regulates, and is regulated by, clock genes in
some of these areas. Thus, it is likely that dopamine is essential to mechanisms that
maintain proper rhythmicity of these five brain areas. This review discusses studies
that showcase different dopaminergic mechanisms that may be involved with the
regulation of these brain areas’ circadian rhythms. Mechanisms include how dopamine
and dopamine receptor activity directly and indirectly influence clock genes and proteins,
how dopamine’s interactions with gap junctions influence daily neuronal excitability, and
how dopamine’s release and effects are gated by low- and high-pass filters. Because the
dopamine neurons described in this review also release the inhibitory neurotransmitter
GABA which influences clock protein expression in the retina, we discuss articles that
explore how GABA may contribute to the actions of dopamine neurons on circadian
rhythms. Finally, to understand how the loss of function of dopamine neurons could
influence circadian rhythms, we review studies linking the neurodegenerative disease
Parkinson’s Disease to disruptions of circadian rhythms in these five brain areas. The
purpose of this review is to summarize growing evidence that dopamine is involved in
regulating circadian rhythms, either directly or indirectly, in the brain areas discussed
here. An appreciation of the growing evidence of dopamine’s influence on circadian
rhythms may lead to new treatments including pharmacological agents directed at
alleviating the various symptoms of circadian rhythm disruption.
Keywords: circadian rhythms, dopamine, retina, olfactory bulb, striatum, midbrain, hypothalamus, Parkinson’s
disease
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INTRODUCTION
Our daily lives operate on 24-h cycles that are regulated by
circadian rhythms. Circadian rhythms synchronize our biological
processes, including body temperature, hunger, sleep, gene
transcription, and sensory perceptions, to manifest and repeat
during specific times each day. The field of circadian rhythm
research continues to expand, and it is becoming apparent
just how crucial it is to our health to follow these daily
rhythms. For example, those in today’s constantly working
society often experience disruptions in their natural circadian
rhythms from nightshifts, jet lag, social jet lag (often experienced
by adolescents and high-school students who wake up at an
earlier time than their biological clocks demand), and overall
short or fragmented nighttime sleep. These disruptions may
increase risks of developing cardiovascular disease (Dominguez-
Rodriguez et al., 2009), cancer (Schernhammer et al., 2006),
obesity (McHill et al., 2014), and metabolic syndrome (Sookoian
et al., 2007; Dochi et al., 2009). Therefore, it is becoming crucial
to understand not only how circadian rhythms regulate daily
biological processes, but also their molecular framework. Such
an understanding may be beneficial to formulating treatment
strategies for the above conditions, as well as redefining
societal expectations and pressures to work during the biological
night.
Human and vertebrate circadian rhythms are synchronized
by the master circadian pacemaker, the SCN, which resides in
the hypothalamus above the optic chiasm. The SCN entrains
circadian rhythms throughout the body, and it does so by
receiving light information from the melanopsin-expressing
ipRGCs, via the retinohypothalamic tract (Gooley et al., 2001;
Hattar et al., 2006; see Figure 1 in Mendoza and Challet, 2014).
On a molecular level, the SCN and other cells maintain their own
circadian rhythms through feedback loops between canonical
circadian clock genes and proteins (here on referred to as “clock”
genes and proteins). Clock genes include Bmal1, Clock, Per1
and 2, Cry1 and 2, Npas2, and Rev-erbα, and their protein
derivatives BMAL1, CLOCK, PER 1 and 2, CRY 1 and 2, NPAS2,
and REV-ERBα (Lowrey and Takahashi, 2011; Mohawk et al.,
Abbreviations: AC, adenylate cyclase; AC1, adenylate cyclase isoform 1; AHr, aryl
hydrocarbon receptor; CRY, cryptochrome (clock gene and protein variant); CT,
circadian time; Cx36, Connexin 36 (gap junction channel); D1,2,3,4,5, dopamine
receptors 1, 2, 3, 4, and 5; DA, dopamine; DOPAC, 3,4-Dihydroxyphenylacetic
acid; EPSC, excitatory postsynaptic current; ETC, external tufted cell (olfactory
bulb); GL, glomerular layer (olfactory bulb); HVA, homovanillic acid; ipRGC,
intrinsically photosensitive retinal ganglion cells; JGCs, juxtaglomerular cells
(olfactory bulb); M/TCs, mitral/tufted cells (olfactory bulb); MPTP, 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (neurotoxin that induces Parkinson’s-like
symptoms); NAcc, nucleus accumbens; NPAS2, neuronal PAS domain-containing
protein 2 (clock gene and its protein variant); OB, olfactory bulb; ONL, olfactory
nerve layer (olfactory bulb); OSN, olfactory sensory neuron (olfactory bulb);
P, postnatal day; PD, Parkinson’s disease; PER, period (clock gene and protein
variant); PET, positron emission tomography; PGC, periglomerular cell; PKA,
protein kinase A; PRL, prolactin; RBD, REM sleep behavior disorder; REM,
rapid-eye movement; RGC, retinal ganglion cells; RLS, restless leg syndrome;
SAC, short axon cell (olfactory bulb); SCN, suprachiasmatic nucleus; SN,
substantia nigra (pars compacta and pars reticulata); SNc, substantia nigra
pars compacta; TH, tyrosine hydroxylase; TIDA, tuberoinfundibular dopamine
neurons (hypothalamus); VIP, vasoactive intestinal polypeptide; VTA, ventral
tegmental area; ZT, Zeitgeber time.
2012). The core circadian feedback loop formed from interactions
between these genes and proteins is as follows: CLOCK and
BMAL1 bind to the promoter regions of Per and Cry, initiating
transcription of these genes; the protein products, PER and CRY,
form a complex that enters the cell’s nucleus and represses the
transcriptional activity of CLOCK and BMAL1, subsequently
stopping Per and Cry transcription (Lowrey and Takahashi,
2011; Mohawk et al., 2012). This loop repeats every 24 h. Each
step of the loop is synchronized (entrained) to a specific time
point. Light and other environmental cues entrain each circadian
mechanism to a specific ZT (“time giver”). Without light or
other external cues, the internal clock oscillates on what is called
CT. CLOCK and BMAL1 also target the promoter regions of
other genes, which drive other circadian feedback loops and
biological processes, depending on the cell. Along with the SCN,
other neuromodulators contribute to the proper cycling of clock
genes and proteins, which overall keeps these biological processes
running on time.
Dopamine, a neurotransmitter well known for regulating
movement, reward, and learning, is emerging as one of the
neuromodulators of central and peripheral circadian rhythms.
Studies of both the SCN and peripheral brain areas have shown
explicit and potential evidence of DA modulating, or being
modulated by, neuronal clock genes, proteins, and rhythms.
This review focuses on five of those brain areas: the retina,
OB, striatum, midbrain, and hypothalamus (See Supplementary
Table 1).
Dopamine is a well-known modulator of circadian rhythms
in the retina. In particular, the circadian release of vertebrate
retinal DA (either endogenously expressed in the interplexiform,
amacrine, or both cells, depending on the species) allows for
proper light adaptation and transmission of light information
to the SCN, via the melanopsin-expressing ipRGCs (Gooley
et al., 2001; Hattar et al., 2006; Popova, 2014; Prigge et al.,
2016). The neuronal circuitry of the retina is morphologically
similar to that of the OB, and the OB also expresses DA
in the glomerular interneurons. Our lab has found a diurnal
variation in DA release in the OB (Corthell et al., 2013), which
may suggest that DA is involved in neuromodulation of OB
circadian rhythms (see Mendoza and Challet, 2014). In the dorsal
striatum, dopaminergic input is required for proper modulation
of PER2 (Hood et al., 2010), and DA receptors regulate clock
gene expression in the striatum in vitro (Imbesi et al., 2009).
Additionally, TH (the rate-limiting enzyme in DA synthesis) has
diurnal variation in the striatum and dopaminergic projecting
neurons from the midbrain (Webb et al., 2009), and TH is
also regulated by clock genes in the midbrain (McClung et al.,
2005; Webb et al., 2009; Chung et al., 2014; Sidor et al.,
2015). Lastly, we include the hypothalamus because it houses
the SCN and because of its circadian-controlled homeostatic
functions, including the circadian-like modulation of PRL release
by the dopaminergic tuberoinfundibular neurons (Freeman et al.,
2000; Bertram et al., 2010). This review does not explore DA
modulation of circadian rhythms in the hippocampus. However,
the hippocampus’ circadian clock may be involved in mood
regulation and neurogenesis (see review by McCarthy and Welsh,
2012), which can be potential targets of DA’s mesolimbic pathway.
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To validate the importance of DA to circadian rhythms
in humans and rodents, the neurodegenerative disorder, PD,
is also explored. Affecting millions worldwide, PD destroys
dopaminergic neurons of the SNc, leading to common motor
symptoms (e.g., bradykinesia, rigidity, tremor) (Carlsson, 1972).
Among classes of DA receptors, D1 and D2 receptors play a
central role in the pathogenesis of PD (Videnovic and Golombek,
2013). Dysfunction of dopaminergic populations in brain regions
including the midbrain, striatum, retina, OB, and hypothalamus
also may lead to other circadian symptoms of PD such as altered
locomotor activity (Fifel and Cooper, 2014), sleep disturbances
(Turjanski et al., 1999; Eisensehr et al., 2003; Lima et al.,
2007; Chaudhuri and Schapira, 2009; Lima, 2013; Videnovic
and Golombek, 2013), visual dysfunction (see Archibald et al.,
2009; Chaudhuri and Schapira, 2009; Popova, 2014), olfactory
dysfunction/hyposmia (Doty et al., 1988; Huisman et al., 2004;
Ross et al., 2008; Lelan et al., 2011; Doty, 2012), and disruptions
to cyclic PRL release (Murri et al., 1980; Bellomo et al., 1991;
Winkler et al., 2002). Recent evidence suggests that PD may affect
circadian rhythms and their cellular mechanisms differently in
the peripheral hypothalamus than in the SCN (Gravotta et al.,
2011; Kudo et al., 2011; Hayashi et al., 2013; Mattam and Jagota,
2015).
Dysregulation and alterations in circadian genes are
commonly observed in people and animal models with PD
(Cai et al., 2010; Kudo et al., 2011; Hayashi et al., 2013; Anderson
and Maes, 2014). Oxidative stress, a potential inducer of PD,
may be regulated by clock genes (see Anderson and Maes,
2014). Per1 and Per2 regulate cAMP activity, which regulates
the AHr (Anderson and Maes, 2014). A dysregulation of cAMP,
potentially through the desynchronization of Per1 and Per2,
can lead to an AHr-induced reduction in melatonin synthesis
(Anderson and Maes, 2014). A decrease in melatonin, which
is an antioxidant, can lead to mitochondrial dysfunction and
atrophy of SNc’s dopaminergic neurons (Anderson and Maes,
2014), potentially leading to PD-like symptoms.
In regard to studies of PD, it should be noted that limitations to
various animal models of this disease exist (see Fifel and Cooper,
2014). For example, most transgenic mouse models of PD do
not show a selective and/or progressive neurodegeneration of DA
neurons (Dawson et al., 2010). In addition, the acute nature of the
insult on DA neurons in neurotoxin-based models differs from
the slow, progressive, age-dependent neurodegeneration of DA
neurons seen in PD (Maetzler et al., 2009; Chesselet and Richter,
2011). Thus, many of these models lack the key motor and non-
motor disruptions observed in PD patients (see Fifel and Cooper,
2014). That being said, data from studies using animal models of
PD are included in this review to fill gaps in data from human
studies.
The study of DA as a neuromodulator can provide additional
understanding to what is already known about the molecular
and neuronal mechanisms that drive the circadian rhythms of
the brain and other areas. Furthermore, this knowledge could
lead to pharmacological therapies aimed at correcting abnormal
neuronal mechanisms in those with disrupted circadian rhythms,
and, potentially, pharmacological therapies to alleviate symptoms
of PD.
RETINA
The retina (see Figure 1 in Popova, 2014) is the first region of
the nervous system to receive and process light, before sending
the visual information to the rest of the brain. The retina
supplies light information to the SCN via the retinohypothalamic
pathway, and it is critical for entrainment of the body’s circadian
rhythms (Gooley et al., 2001; Hattar et al., 2006). The neurons of
the retina, as those of the OB, can also maintain the synchrony
of their circadian rhythms independent of the SCN (Doyle et al.,
2002a,b; Granados-Fuentes et al., 2006; Ruan et al., 2008; Jaeger
et al., 2015), and DA has been directly linked to the regulation of
circadian rhythms of retinas in vitro (Doyle et al., 2002a,b; Ruan
et al., 2008).
Daily Rhythm of Retinal Dopamine
Content Depends on Retinal Melatonin
The mammalian and fish retinas have a daily rhythm of DA
content, which peaks during the daytime hours and falls during
the nighttime hours (Doyle et al., 2002a,b; Ribelayga and Mangel,
2003). This retinal DA rhythm appears to be dependent on
melatonin, a hormone that helps to induce sleep during darkness
(Doyle et al., 2002a). In the Doyle et al. (2002a) study, a
mouse strain (C57BL/6J) was used that was unable to produce
endogenous melatonin, and, as a result, the circadian rhythm
of retinal DA levels was lost in constant darkness. With the
application of exogenous melatonin to the mouse retina, DA
rhythmicity in constant darkness was restored (Doyle et al.,
2002a). Thus, there may be a mutual inhibition between DA and
melatonin, which leads to daily rhythmicity in the retina (Iuvone,
1986; Cahill and Besharse, 1991, 1995; Doyle et al., 2002a).
On the other hand, the rhythm of DA content in the retina
may not depend on the integrity of the retina’s photoreceptor
cells (Doyle et al., 2002b). The rat strain RCS/N-rdy, whose
photoreceptors degenerate after 18 days of age, had an unaltered
daytime rhythm of DA, both in 12-h light/dark cycles and
in constant darkness (Doyle et al., 2002b). In the absence of
photoreceptors, the unaltered rhythmicity of retinal DA may be
entrained by ipRGCs, as these cells send glutamatergic signals to
postsynaptic dopaminergic cells (Prigge et al., 2016). This Doyle
et al. (2002b) study also confirmed that retinal contents of DA
and its metabolites are higher during the daytime rather than
nighttime. This finding is consistent with that of Di Paolo et al.
(1987), who showed that postmortem human retinas had higher
DA concentrations when the person died during the daytime
rather than the nighttime (Di Paolo et al., 1987). This is also
consistent with the finding that light increases retinal TH activity
and DA turnover in the rat retina (Iuvone et al., 1978).
Dopamine Receptors’ Vast Effects on
Retinal Light Adaptation and Circadian
Rhythms
The vertebrate retina expresses two classes of DA receptors:
D1-like receptors (which includes D1 and D5 receptors) and
D2-like receptors (which includes D2, D3, and D4 receptors,
although D3 may not be present in the retina) (Witkovsky, 2004;
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Popova, 2014). D1 receptors are found on horizontal, amacrine,
and bipolar cells, while D5 receptors are found in the retinal
pigment layer (Witkovsky, 2004). Some of the D2 receptors
function as autoreceptors for DA neurons, while D4 receptors
are found on rods and cones photoreceptors, at least in mice
(Witkovsky, 2004).
Evidence suggests that the D1 receptor, but not the D2
receptor, influences the PER2 protein of the retina. Exposing
mouse retinal explant cultures to 1-h pulses of light during CT
13 and CT 19.5 (retinal subjective night) delays retinal PER2
expression by 2.3 h at CT13 and by 1.5 h at CT 19.5 (Ruan et al.,
2008). The in vitro expression of retinal PER2 is also affected
by the D1 receptor antagonist, SCH-23390, and a 1-h pulse of
light at CT 13 (Ruan et al., 2008). SCH-23390 applied during the
1-h light pulse decreased the PER2 expression delay significantly
compared to the effects of light exposure alone (Ruan et al., 2008).
Without light exposure, application of the D1 receptor agonist,
SKF38393, at CT 13 induced a delay of PER2 expression by 1 h
(Ruan et al., 2008). Conversely, activating the D2 receptor with
the agonist quinpirole, applied at CT 13, does not affect the timing
of the PER2 expression (Ruan et al., 2008).
Activation of the D2 receptor induces Per1 transcription
through the recruitment of the CLOCK:BMAL1 heterodimer,
an action that was shown to be specific to neurons (Yujnovsky
et al., 2006). The D2 receptor also may regulate the rhythmic
transcription of melanopsin mRNA in ipRGCs (Sakamoto et al.,
2005), possibly influencing light entrainment signals being sent
to the SCN. Additionally, DA appears to inhibit the activity of
melatonin and aralkylamine N-acetyltransferase (AA-NAT, also
known as serotonin N-acetyltransferase), a key enzyme in the
production of melatonin (Iuvone, 1986; Cahill and Besharse,
1991). This inhibition was shown to be mediated through the D2
receptor, because D2 agonists, such as LY171555 and quinpirole,
mimicked DA’s inhibition of AA-NAT activity (Iuvone, 1986) and
melatonin release (Cahill and Besharse, 1991) and also mimicked
the effects of light exposure (Iuvone, 1986; Cahill and Besharse,
1991).
Without retinal DA, cone-driven light adaptation (indicative
of nighttime to daytime transition), contrast sensitivity, and
visual acuity decrease (Jackson et al., 2012). Dopaminergic
modulation of these retinal functions appears to be largely
through the activity of D1 and D4 receptors (Jackson et al., 2012).
Both receptors appear to increase the light-adapted amplitude
of a b-wave (representative of ON-bipolar cell functionality);
however, visual acuity appears to only be impacted by D1
receptors, and contrast sensitivity, by D4 receptors (Jackson et al.,
2012; Hwang et al., 2013). Daytime contrast sensitivity, in turn,
is also regulated by RGCs that express the clock protein NPAS2
(Hwang et al., 2013). Interestingly, DA, through activation of
the D4 receptor, influences the proper expression of the Npas2
gene, and regulates contrast sensitivity (Hwang et al., 2013).
The activation of NPAS2 likely drives the activity of RGC’s AC1
(Hwang et al., 2013). Support for this hypothesis comes from
the finding that expression of the D4 receptor gene, D4d (which
fluctuates on a circadian rhythm similar to that of retinal DA), is
necessary for the expression of Adcy1, a gene that produces AC1
(Jackson et al., 2011). This was confirmed with pharmacological
manipulation, where the D4 antagonist, L745870, decreased the
daytime expression of Adcy1 (Jackson et al., 2011). Therefore,
activation of the D4 receptor, during the daytime, is required for
rhythmic fluctuation of cAMP through the regulation of AC1,
and thus, contrast sensitivity and other downstream effects of the
second messenger system (Jackson et al., 2011, 2012; Hwang et al.,
2013).
Recent additional evidence also suggests that D4 receptors are
involved in light adaptation (Prigge et al., 2016). Melanopsin-
containing M1 ipRGCs, involved in sending light information
for circadian photoentrainment (Gooley et al., 2001; Hattar et al.,
2006), have been shown to presynaptically activate dopaminergic
amacrine cells (Prigge et al., 2016). Mice without viable M1
ipRGCs have impaired light adaptation, which was rescued by the
D4 receptor agonist, PD168077 (Prigge et al., 2016). D4 receptors
expressed on cone photoreceptors (Witkovsky, 2004) allow for
proper presynaptic feedback from active M1 ipRGCs and DA
amacrine cells and optimal light adaptation (Prigge et al., 2016).
Dopamine’s Modulation of Retinal Gap
Junction Channels
The retina is rich in gap junctions, which contribute to different
retinal functions by coupling (opening) and uncoupling (closing)
to allow and block fast current transmission between retinal
neurons. Some of these functions may be to set the period of
retinal oscillators (Jaeger et al., 2015). Layers of the mammalian
retina in vitro were found to have different oscillators, which
oscillate on a 26-h period (Jaeger et al., 2015). This independent
oscillation was shown to be due to gap junction coupling between
the retinal layers (Jaeger et al., 2015). One of the layers that
expresses an independent period is the inner nuclear layer (Jaeger
et al., 2015), which contains the dopaminergic amacrine cells.
Retinal AII amacrine cells, which are important for rod
photoreceptor-mediated vision, adapt to light environments by
communicating with neighboring AII amacrine cells through
the gap junction channel Cx36 (Kothmann et al., 2009). The
uncoupling mechanism of retinal Cx36 channels is modulated
by DA, released from neighboring amacrine cells (Kothmann
et al., 2009). This effect is mediated by DA’s action on
the D1 receptor, which activates the following intracellular
mechanism: D1 receptor’s GαS protein activates AC and PKA,
which phosphorylates protein phosphodiesterase 2 A, which
dephosphorylates the serine 293 residue of the Cx36 channel,
effectively uncoupling and shutting the channel (Kothmann
et al., 2009). This mechanism blocks off communication between
neighboring amacrine AII cells (Kothmann et al., 2009). Since
DA uncouples amacrine cells’ Cx36 gap junctions by activating
the above-described D1 receptor-driven mechanism (Kothmann
et al., 2009), it may be that another D1 receptor-driven
mechanism could set the phase of PER2 in amacrine and other
retinal cells (Ruan et al., 2008; Jaeger et al., 2015).
In the fish retina, horizontal H1 cells are also coupled via
gap junction channels, which the D1 receptor also uncouples
during the day (Ribelayga and Mangel, 2003). An interesting
observation from this study was that these gap junctions were
coupled to each other in constant darkness (during the subjective
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day and subjective night) (Ribelayga and Mangel, 2003). This
implies that the circadian-driven DA release was not enough to
uncouple these gap junctions, because either photopic light or
the D1 receptor agonist SKF38393 was required to significantly
uncouple these gap junctions (Ribelayga and Mangel, 2003). This
may be due to the fact that, unlike D2-like receptors, D1 receptors
are less sensitive to DA, and the DA release during the circadian
subjective day was too low to surpass the threshold for D1
activation and gap junction uncoupling (Ribelayga and Mangel,
2003). However, because D2-like receptors are more sensitive
to DA, then the circadian-driven DA release could be enough
to regulate gap junctions of other cells (Ribelayga and Mangel,
2003).
In the photoreceptor layer, the D2-like D4 receptors
regulate the coupling of gap junctions between rod and cone
photoreceptors (Ribelayga et al., 2008; Li et al., 2013; Jin et al.,
2015; Zhang et al., 2015). Unlike the fish horizontal H1 cells,
the gap junctions between the fish photoreceptors were able
to couple during the subjective night and uncouple during the
subjective day (Ribelayga et al., 2008). The uncoupling of these
gap junctions is mediated by D2-like receptor activation, both
in fish and mouse retinas (Ribelayga et al., 2008). Increased
nighttime coupling (when DA levels are low) would, therefore,
increase rod-driven dim light transmission through other rods
and cones (Ribelayga et al., 2008). This nighttime transmission
would increase the signal-to-noise ratio of transduction of dim
light, but coupled rods’ response to single-photons would be
decreased (Jin et al., 2015). It has been confirmed that the gap
junction channel between these photoreceptors is Cx36, mediated
by D4 receptors, which uncouple Cx36 through inhibition of
the AC/PKA pathway (Li et al., 2013). Interestingly, adenosine
and its receptor, A2aR, which also have rhythmic expression,
appear to increase the nighttime coupling of photoreceptor Cx36
by activating the AC/PKA pathway (Li et al., 2013). Finally,
it was confirmed that Cx36 channel phosphorylation (leading
to coupling) fluctuates on a circadian scale and that photopic
light decreases Cx36 phosphorylation (Zhang et al., 2015). These
studies show that DA influences the gap junction uncoupling
through several layers of the retina, both in fish and mice.
Uncoupling of the photoreceptor gap junctions via D4 may
influence the contrast sensitivity of the retina, while uncoupling
through D1 receptors may influence the visual acuity (Jackson
et al., 2012).
The Co-release/Co-transmission of DA
and GABA in the Retina
Retinal amacrine cells have been shown to release both DA and
γ-amino butyric acid (GABA) (Hirasawa et al., 2009), although it
is not clear whether these two neurotransmitters are co-released
(same synaptic vesicle) or co-transmitted (same neuron, but
different synaptic vesicles) (Vaaga et al., 2014). GABA proves
to be important in the regulation of retinal circadian rhythms,
because it decreases the amplitude of PER2 levels in the retina
in a dose-dependent manner (Ruan et al., 2008). Because retinal
GABA is an important neurotransmitter in modulating the clock
proteins of the retina (Ruan et al., 2008), then GABA release by
dopaminergic neurons in the OB (Maher and Westbrook, 2008;
Kosaka and Kosaka, 2009; Kiyokage et al., 2010; Liu et al., 2013),
the midbrain (Tritsch et al., 2012; Chuhma et al., 2014), and
the hypothalamus (Zhang and van den Pol, 2015) may also be
important in the modulation of circadian-like activities.
Parkinson’s Disease and the Retina
Patients with PD have a number of types of visual dysfunction,
some which may relate to altered retinal DA levels (see Archibald
et al., 2009). Studies have shown that PD patients have thinner
inner retinal layers, where endogenous dopaminergic amacrine
cells reside (specifically, in the inner plexiform layer) (Witkovsky,
2004; Hajee et al., 2009; Adam et al., 2013; Spund et al., 2013).
Disruptions of retinal dopaminergic neurons resulting in reduced
retinal DA levels (Nguyen-Legros, 1988; Harnois and Di Paolo,
1990) may contribute to visual symptoms such as impaired foveal
vision (Bodis-Wollner, 2009), contrast sensitivity (Bulens et al.,
1989; Popova, 2014), and light adaption (Prigge et al., 2016)
in patients with PD (Archibald et al., 2009). Impaired color
and contrast discrimination may be a preclinical signs of PD
(Chaudhuri and Schapira, 2009).
Decreased retinal DA levels in PD patients also have
potential implications to circadian function. In mammals, photic
entrainment of circadian rhythms occurs when ipRGCs convey
photic signals to the SCN via the retinohypothalamic pathway
(Gooley et al., 2001; Hattar et al., 2006). DA has been shown
to regulate rhythmic melanopsin mRNA expression of these
ipRGCs, possibly via actions at D2 receptors (Sakamoto et al.,
2005). Dopaminergic amacrine cells in the retina also express
circadian rhythms in expression of clock genes (Dorenbos et al.,
2007).
OLFACTORY BULB
The first region of the nervous system to receive and process
odorant information is the mammalian OB (see Figure 11 in
Kosaka and Kosaka, 2016). Chemical odorants activate OSNs
in the olfactory epithelium, which transmit odor signals to
neurons in the GL of the OB. Synaptic contact between the OSNs
and OB neurons occurs in discreet spherical structures known
as glomeruli, where OSNs form glutamatergic axodendritic
synapses with the main OB output neurons, mitral and tufted
cells (M/TCs) (Berkowicz et al., 1994; Ennis et al., 1996), as
well as local interneurons (Ennis et al., 2001). Surrounding
the glomeruli, three morphologically distinct populations of
interneurons exist: PGCs, SACs, and ETCs (Golgi, 1875;
Shepherd, 1972; Shepherd et al., 2011; Nagayama et al., 2014).
Collectively, these interneurons are known as JGCs. In addition
to having synaptic contacts with each other, JGCs target both
OSN terminals and M/TCs (Shepherd, 1972; Hsia et al., 1999;
Berkowicz and Trombley, 2000; Ennis et al., 2001; Davila et al.,
2003; Nagayama et al., 2014). Dopaminergic OB neurons are
JGCs that are found in the GL (Baker, 1986; Ennis et al., 2001;
Kosaka and Kosaka, 2009). An estimated 11% (∼87,000 neurons)
of JGCs in the mouse OB are dopaminergic (Parrish-Aungst
et al., 2007), while the adult rat has an estimated 100,000–150,000
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dopaminergic neurons in the GL (McLean and Shipley, 1988). DA
receptors are found throughout the entire OB, with D1 receptors
localizing in all layers but the ONL, and D2 receptors heavily
localizing in the GL and ONL (Nickell et al., 1991; Hsia et al.,
1999; Berkowicz and Trombley, 2000; Ennis et al., 2001; Davila
et al., 2003).
As in the retina, the OB has been shown to have circadian
rhythms that are independent of the master circadian pacemaker,
the SCN, allowing the OB to maintain its daily rhythmicity
in vitro (Granados-Fuentes et al., 2004a,b). However, the
neuronal mechanisms that drive the independent circadian
activity of the OB are not well known. DA, which has a daily
rhythm of release in the rat OB (Corthell et al., 2013), may be
involved in modulating the circadian activity of the OB via a
variety of mechanisms (and DA itself may be regulated through
circadian mechanisms) (Mendoza and Challet, 2014).
Daily Dopamine Activity in the Olfactory
Bulb
In the rat OB, DA content rhythmically fluctuates depending on
the light cycle (Corthell et al., 2013). The overall activity was
determined by measuring the ratio of DA’s metabolite, DOPAC
(representative of DA release), to DA every 2.5 ZT hour (Corthell
et al., 2013). DOPAC/DA ratios were shown to be highest during
ZT 0-12 (lights turned on) and lowest during ZT 13-24 (lights
turned off) (Corthell et al., 2013). Since DA release follows a
diurnal variation, it may be that circadian activity in the OB also
occurs in dopaminergic neurons (Mendoza and Challet, 2014).
Dopamine’s Presynaptic Inhibition of
Olfactory Sensory Neurons
An abundance of electrophysiological data has shown that DA,
released by JGCs, presynaptically inhibits transmission between
OSNs and OB neurons by activating D2 receptors on OSN
terminals (Hsia et al., 1999; Berkowicz and Trombley, 2000; Ennis
et al., 2001). A subsequent study by our group showed that
DA also inhibits excitatory transmission between M/TCs and
interneurons by a presynaptic mechanism involving D2 receptors
(Davila et al., 2003). In addition, DA also induces excitation
in postsynaptic interneurons via the D1 receptor (Liu et al.,
2013). Through these actions, and the diurnal release of DA, it is
hypothesized that DA sharpens synaptic processing of olfactory
information by diminishing tonic odorant noise (Berkowicz and
Trombley, 2000; Ennis et al., 2001).
Since OSNs and M/TCs excite their postsynaptic targets
via glutamate release, DA’s presynaptic inhibition decreases
the release of glutamate onto postsynaptic targets, effectively
keeping them from becoming excited and transmitting the odor
signals to higher brain regions (Hsia et al., 1999; Berkowicz
and Trombley, 2000; Ennis et al., 2001). Inhibition by DA
appears to be presynaptic, because application of exogenous
DA did not change the kinetics of the postsynaptic response
of M/TCs to olfactory nerve stimulation, indicating that both
NMDA and AMPA/kainate receptor-mediated components were
affected equally (Berkowicz and Trombley, 2000). Also, DA did
not directly affect currents evoked by exogenous application of
glutamate to cultured OB neurons (Berkowicz and Trombley,
2000; Davila et al., 2003). Further supporting a presynaptic
mechanism, DA altered the ratio between the conditioning and
the test response amplitude recorded in postsynaptic neurons
in rat OB slices, thereby attenuating the degree of paired-pulse
depression (Ennis et al., 2001).
Dopamine May Act as a High-Pass Filter
for Olfactory Bulb Signal Transduction
All neurons that store and release chemical neurotransmitters via
vesicular exocytosis have the potential to deplete their vesicular
storage with a high-frequency stimulus. Conversely, neurons may
not release any vesicles if the signal is too low in frequency.
Most neurons are gated to a specific frequency that would allow
for vesicular exocytosis. Therefore, neurotransmitters that are
released by low-frequency, but not high-frequency, stimuli are
regulated by a low-pass filter, while neurotransmitters that are
released by high-frequency, but not low-frequency, stimuli are
regulated by a high-pass filter. The release of DA in the OB may
be gated by a low frequency, suggesting that a low-pass filter is
needed for DA release. However, DA itself may influence OB
signal transduction as a high-pass filter.
Theta frequency (4–10 Hz), which is observed in the OB’s
GL (Fukunaga et al., 2014), may be needed to release DA and
other neurotransmitters. Theta frequency is also implied to be the
sniffing frequency at which rodents sample odors (Wachowiak,
2011; Liu et al., 2013; Genovese et al., 2016), and this low
frequency could also increase the signal-to-noise ratio. Therefore,
if OB DA is released while sniffing at a theta frequency, DA
release may inhibit low, tonic odor transmission. If a nocturnal
animal is sampling odors while awake (when OB DA content
is low), or while asleep during the day (when OB DA content
is high), potent odors may activate dopaminergic interneurons
so frequently that eventually the vesicular DA storage will be
depleted. Additionally, constant DA release and binding can
desensitize the presynaptic D2 receptors on OSNs (Beaulieu et al.,
2007; Clayton et al., 2014). Constant D2 receptor activation would
lead to phosphorylation of these receptors by G-protein receptor
kinases, which would recruit the arrestin proteins, eventually
leading to an internalization of the receptor (Beaulieu et al., 2007;
Clayton et al., 2014). Thus, DA release may be gated by a low-pass
filter, but DA activity, itself, may act as a high-pass filter, allowing
for only those odors that surpass a threshold to be transmitted.
Dopamine and GABA Co-release in the
Olfactory Bulb
In the OB, nearly 97% of all DA JGCs co-express glutamate
decarboxylase 67, the rate-limiting enzyme in GABA production
(Kiyokage et al., 2010), indicating that GABA is released from
DA cells (Maher and Westbrook, 2008; Kosaka and Kosaka,
2009; Borisovska et al., 2013; Liu et al., 2013). It is interesting
to note that even though there are species differences between
the chemical composition of rat and mouse OB JGCs, the
dopaminergic neurons of both species largely co-express GABA
(Kosaka and Kosaka, 2007, 2016). One of the JGCs that
co-expresses DA and GABA is the SAC (Hökfelt et al., 1975;
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 April 2017 | Volume 11 | Article 91
fncel-11-00091 March 30, 2017 Time: 13:59 # 7
Korshunov et al. Dopamine’s Role in Circadian Rhythms
Kosaka and Kosaka, 2008; Kiyokage et al., 2010; Liu et al., 2013).
Evidence suggests that SACs release both GABA (inhibition
through GABAA receptor) and DA (excitation through D1
receptor) onto neighboring and distant glomeruli, generating a
biphasic inhibition-excitation response (Liu et al., 2013).
The DA-GABA co-release mechanism may be linked to a
rodent’s sampling rate of novel odors (Liu et al., 2013). SACs
form synapses with ETCs, which release glutamate onto all other
OB interneurons and the main output cells, M/TCs (Liu et al.,
2013; Nagayama et al., 2014). GABA and DA, co-released from
SACs, lead to a temporal, biphasic inhibition-excitation response
in ETCs (Liu et al., 2013), which facilitates or dampens the
transmission of olfactory signals to higher brain regions (Liu
et al., 2013). A feed-forward inhibition of M/TCs also would
occur when some ETCs activate GABAergic PGCs (Liu et al.,
2013). These GABA and DA actions may indirectly allow some
M/TCs to send odor signals, while other M/TCs are briefly
inhibited. Therefore, a rodent may process important odors (e.g.,
predators, food) more selectively while it is sleeping during the
day, which is when OB DA activity is reported to be highest
(Corthell et al., 2013).
Biophysical Properties and Daily
Expression of the Connexin 36 in the
Olfactory Bulb
As in the retina, Cx36 gap junction channels are expressed in the
OB (Belluardo et al., 2000; Christie and Westbrook, 2006) and
play a crucial role in the transmission of the odorant signals in
the OB within the mitral cells (Christie and Westbrook, 2006).
Specifically, mitral cell dendrites couple to each other in their
respective glomeruli, allowing for lateral excitation (Christie and
Westbrook, 2006). Cx36 channels help to amplify an odorant
signal sent from the sensory neurons onto the mitral cells by
having depolarization spread from one mitral cell to the other
neurons coupled to it (Christie and Westbrook, 2006). Cx36
channels were confirmed to be involved in mitral cell lateral
excitation, because Cx36 knock-out mice did not show lateral
excitation of mitral cells within the same glomerulus (Christie
and Westbrook, 2006).
Cx36 mRNA has a daily expression rhythm in the OB of
the rat, with highest expression during nighttime and lowest
expression during daytime (Corthell et al., 2012), out of phase
with DA release (Corthell et al., 2013). This may imply that Cx36
gap junctions also play a role in the diurnal rhythm of olfactory
acuity in rodents (Granados-Fuentes et al., 2006, 2011). And, if
DA plays a role in uncoupling Cx36 channels of the mitral cells,
as it does in inhibiting glutamate release from mitral cells (Davila
et al., 2003), then DA may further dampen an odor signal being
sent from a mitral cell by inhibiting lateral excitation among
mitral cells.
The Olfactory Bulb Maintains Its Own
Daily Rhythms
Increasing evidence suggests that the OB may function as
an independent circadian system controlling daily changes in
olfaction (Miller et al., 2014). For example, the OB exhibits
intrinsic circadian rhythms in firing rate and clock gene (Per1)
activity in vitro (Granados-Fuentes et al., 2004b). Interestingly,
daily rhythms in the OB and olfactory discrimination persist
when circadian rhythms are eliminated in the SCN (Abraham
et al., 2005) or when the SCN is ablated (Granados-Fuentes
et al., 2004a). A later study from this group showed that daily
rhythms in olfactory discrimination in mice depend on clock
gene expression but not the SCN (Granados-Fuentes et al., 2011),
while the SCN is still necessary for entrainment of the OB in the
intact animal (Granados-Fuentes et al., 2004a). More recently,
this group showed that VIP regulates circadian rhythms in gene
expression and odor detection performance in the OB (Miller
et al., 2014). Data from our lab suggesting diurnal variations in
DA release in the OB (Corthell et al., 2013) raise the possibility
of circadian activity of dopaminergic cells in the OB as well
(Mendoza and Challet, 2014).
Dopamine in the Human Olfactory Bulb
Dopamine’s presynaptic mechanism of inhibiting glutamate
release from the OSNs in turtles and mice (Berkowicz and
Trombley, 2000; Ennis et al., 2001) also may be present
in the human OB, since human OBs have been shown to
have dopaminergic neurons in the GL (Alizadeh et al., 2015).
Interestingly, when labeling postmortem human brains with the
TH antibody, it was shown that younger (35 years and under)
postmortem OBs had less TH-positive cells than older (50 years
and over) postmortem OBs (Alizadeh et al., 2015). Rodents also
show an increase in OB dopaminergic neurons with age (Kosaka
and Kosaka, 2009). This increase in dopaminergic neurons in
older OBs may be caused by the progression of PD, as discussed
below.
Alizadeh et al. (2015) have proposed that younger people tend
to detect odors better than older people (confirmed previously
by Doty et al., 1984), because the over suppression of olfactory
information processing by DA presynaptically inhibits the release
of glutamate from OSNs onto mitral cells in older people (Doty
and Risser, 1989; Alizadeh et al., 2015). Although this presynaptic
DA action is proposed to sharpen odor detection by filtering
noise (Berkowicz and Trombley, 2000; Ennis et al., 2001), an
increase in DA OB neurons may suggest excessive DA activity.
Based on the previous cited evidence (Ennis et al., 2001; Davila
et al., 2003), excessive DA activity could lead to a saturation
of D2 receptor activation, which would not only block odor
signal transmission by inhibiting glutamate release, but also by
potentially uncoupling Cx36 channels between coupled mitral
cell dendrites.
Parkinson’s Disease and the Olfactory
Bulb
Patients with PD often have types of olfactory dysfunction (Doty
et al., 1988), which can be an early precursor to the development
of PD (Ross et al., 2008). Close relatives of patients with
idiopathic PD are much likelier to develop idiopathic PD and
bradykinesia if they have hyposmia (a diminished sense of smell)
but not normosmia (normal sense of smell) (Berendse et al., 2001;
Ponsen et al., 2004). These and other clinical studies provide
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evidence that non-motor smell tests are superior diagnostic tools
for PD to motor tests, especially in people with mild PD who have
yet to develop bradykinesia (Bohnen et al., 2008). Non-motor
smell tests may serve as predictors of those who will develop PD
(Berendse et al., 2001; Ponsen et al., 2004).
How are the endogenous DA neurons of the OB affected
by PD? Paradoxically, unlike the midbrain and, potentially, the
retina, DA and TH neurons increase in the OBs of patients
with PD (Huisman et al., 2004; Mundinano et al., 2011). An
increase in dopaminergic OB neurons has also been shown
in the transgenic rat line, α-synuclein, which exhibit signs of
olfactory dysfunction that precede signs of motor dysfunction
(Lelan et al., 2011). An increase in DA in the OB can contribute to
hyposmia of PD patients (Huisman et al., 2004) by increasing DA
binding to D2 receptors located on OSNs and M/TCs, causing
a presynaptic inhibition of glutamate release from the OSNs
and M/TCs, effectively inhibiting odor performance (Hsia et al.,
1999; Berkowicz and Trombley, 2000; Ennis et al., 2001; Davila
et al., 2003). This hypothesis is supported by a study in which
administration of the D2 agonist, quinpirole, caused a dose-
dependent decrease in odor detection and performance in rats
(Doty and Risser, 1989). Knockout mice lacking the dopamine
transporter or D2 receptors have also been shown to have an odor
discrimination deficit (Tillerson et al., 2006).
MIDBRAIN’S SUBSTANTIA NIGRA PARS
COMPACTA AND VENTRAL TEGMENTAL
AREA
The striatum (a collective term for the caudate nucleus, NAcc,
and the putamen of the basal ganglia) receives a large input
from the SNc’s dopaminergic neurons through the nigrostriatal
pathway. This dopaminergic input results in the facilitation of
movement through direct (D1 receptor-driven) and indirect (D2
receptor-driven) pathways (see Figure 1 in Nelson and Kreitzer,
2014). In addition to D1 and D2 receptors, the D3 receptor is
expressed in the striatum (most heavily in the NAcc), the SN,
and VTA (see Beaulieu and Gainetdinov, 2011). The D4 and D5
receptors also show minimal expression in the SN (see Beaulieu
and Gainetdinov, 2011). The D2 receptor pathway appears to be
especially important for driving the expression the clock protein
PER2 in the dorsal striatum (Hood et al., 2010). Therefore,
DA may be important in modulating circadian activities of the
striatum, including daily locomotion, something that is lost in
patients with PD.
The midbrain also contains the VTA, from which DA neurons
project to different brain areas, including cortical (mesocortical
projections) and limbic (mesolimbic projections) areas (Russo
and Nestler, 2013). Dopaminergic neurons in the mesolimbic
pathway (often called the reward pathway, see Figure 1 in
Russo and Nestler, 2013) project to the hippocampus, NAcc,
and the amygdala, are important for learning and motivation,
and are well known to be influenced by drugs of abuse. In fact,
prolonged exposure to cocaine in mice increases the expression
of Per1 and Clock mRNA, and it decreases the expression of
Per2, Bmal1, Cry1, and NPAS2 (a paralog of Clock) mRNA in
the striatum (Uz et al., 2005). Cocaine may lead to addictive
behaviors by altering the expression of circadian genes in the
striatum (Uz et al., 2005) by increasing DA activity from the
midbrain.
Dopamine Receptors’ Effects on Clock
Gene and Protein Expression in the
Striatum
The striatum receives a large dopaminergic input, and so it
is not surprising that clock genes and proteins have various
interactions with DA. Cultured mouse striatal neurons have
been shown to express genes for DA receptors 1, 2, and 3,
as well as for clock genes Per1, Clock, Bmal1, and NPAS2
(Imbesi et al., 2009). These DA receptors differently regulate
the expression of these clock genes. Application of the D1
receptor agonist, SKF-38393, increased mRNA levels of all of
the above-mentioned clock genes, while the D2 receptor agonist,
quinpirole, decreased Clock and Per1 mRNA levels (Imbesi et al.,
2009). Additionally, quinpirole injections were shown to increase
nighttime expression of PER1, but decrease the protein’s daytime
expression (Imbesi et al., 2009). The following 2010 study by
Hood et al. (2010) shows that the D2 receptor is necessary for
proper PER2 expression.
In the rat’s dorsal striatum, the expression of PER2 peaks
during the daytime hours, while extracellular DA peaks during
the nighttime hours (Hood et al., 2010). Lesioning DA neurons
via a unilateral injection of 6-hydroxydopamine significantly
decreased the ipsilateral dorsal striatum’s PER2 protein and
mRNA expression 14 days after the injection, without evidence
of restoration (Hood et al., 2010). Injections of α-methyl-para-
tyrosine (AMPT), an inhibitor of TH, decreased DA content and
daytime (ZT 1) PER2 expression, but increased PER2 expression
during nighttime (ZT 13) (Hood et al., 2010). Lastly, the D2
receptor antagonist, raclopride, injected chronically, decreased
PER2 expression at ZT 1, while the agonist quinpirole restored
and reversed the daily PER2 expression in rats previously treated
with 6-hydroxydopamine on the lesioned side (Hood et al.,
2010).
Daily Tyrosine Hydroxylase and
Dopamine Activity in the Midbrain
The expression of VTA’s TH and the firing of dopaminergic
neurons are both linked to a specific time of the day (Webb
et al., 2009; Chung et al., 2014; Dominguez-Lopez et al., 2014;
Sidor et al., 2015). Interestingly, the diurnal variation in VTA’s TH
protein expression appears to out-of-phase with the TH mRNA
expression (Sidor et al., 2015). TH in the VTA is expressed more
during the daytime (around ZT 6) than during the nighttime (ZT
13-24), while TH mRNA is expressed less during the daytime
(ZT 4) than the nighttime (ZT 16, 20) (Webb et al., 2009;
Sidor et al., 2015). Circadian expression of TH mRNA in the
VTA is also low during the subjective day (CT 8 and 12)
and high during the subjective night (CT 20 and 24) (Chung
et al., 2014). Additionally, TH expression appears to be similar
in the VTA and SNc, where both show peak expression at
CT 0 and lowest expression at CT 12 (Chung et al., 2014).
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However, TH expression in the VTA and NAcc is out-of-phase,
with both the peak for VTA TH expression and the trough
for the NAcc TH expression occurring at ZT6 (Webb et al.,
2009).
Tyrosine hydroxylase expression in the VTA is suppressed
by CLOCK (McClung et al., 2005; Sidor et al., 2015) and by
the circadian nuclear receptor REV-ERBα (Chung et al., 2014).
Homozygous Clock mouse mutants have an increased expression
of TH in their VTA (McClung et al., 2005). Higher VTA
expression of TH would cause an increase in DA production
and release in the mesolimbic pathway, likely being one of the
causes for the reported results of Clock mutant mice finding
cocaine more rewarding and expressing higher sensitization
to cocaine (McClung et al., 2005). Rev-erbα knock-out mice
exhibited increased TH mRNA expression and DA release at CT
12 (Chung et al., 2014). Increased TH and DA through loss of
REV-ERBα led to increased mania-like behavior in these mice
(Chung et al., 2014).
Monoamine oxidase A (MAOA), an enzyme that suppresses
DA activity by removing DA’s amine group, is also controlled
by circadian mechanisms. Midbrain’s MAOA function is highly
important in regulating DA activity and, therefore, mood and
movement. MAOA and its mouse gene variant, Maoa, were
found to have rhythmic expression in the VTA, with highest
expression at ZT 6 and lowest at ZT 18 (Hampp et al., 2008).
Conversely, Per2 mutant mice had a flat daily expression of Maoa
and MAOA activity, which unsurprisingly led to higher levels of
DA release and activity (Hampp et al., 2008). Per2 mutants also
experienced less helplessness in a forced swim test compared to
control mice, likely a result of increased DA due to decreased
MAOA (Hampp et al., 2008). The daily rhythmic expression of
TH and MAOA may be a mechanism of daily mood fluctuation
in people.
The firing activity of VTA neurons, as electrophysiology
data show, does not appear to be consistent throughout studies
(Chung et al., 2014; Dominguez-Lopez et al., 2014; Sidor et al.,
2015). In vivo recordings from DA neurons in the VTA showed
that these neurons fire the most spikes during the onset of
daytime (7:00–11:00 h) and onset of nighttime (19:00–23:00 h),
while firing significantly less spikes in between (11:00–15:00 h
and 23:00–3:00 h) (Dominguez-Lopez et al., 2014). Therefore,
a 12-h period for the spike firing frequency is shown in these
VTA neurons (Dominguez-Lopez et al., 2014). However, other
in vivo recording data show a steady firing rate of VTA neurons
(Chung et al., 2014; Sidor et al., 2015). This discrepancy may
be due to inherent species difference, since the twice-daily
highest spiking frequency was found in rats (Dominguez-Lopez
et al., 2014) and the steady firing frequency was recorded in
mice (Chung et al., 2014; Sidor et al., 2015). It may not be
surprising that both CLOCK and REV-ERBα suppress VTA
firing, as they also suppress TH expression (McClung et al., 2005;
Chung et al., 2014; Sidor et al., 2015). Mutant mice without a
functional Clock have higher bursts and firing rates (McClung
et al., 2005; Sidor et al., 2015), while an antagonist of REV-
ERBα, SR8278, increased the firing rate of VTA neurons equally
during two different time points (ZT 1 and 11) (Chung et al.,
2014).
Dopamine’s Presynaptic Inhibition of
Glutamate Release onto the Ventral
Tegmental Area
Similar to the effect of DA on olfactory-nerve-evoked responses
in OB neurons (Hsia et al., 1999; Berkowicz and Trombley,
2000; Ennis et al., 2001), VTA’s DA inhibits glutamate release
presynaptically via the D2 receptor (Koga and Momiyama,
2000). Focal stimulation within the VTA in the presence of
various pharmacological blockers evoked non-NMDA EPSCs in
dopaminergic neurons (Koga and Momiyama, 2000). Addition
of exogenous DA inhibited these EPSCs (Koga and Momiyama,
2000). Repeating these experiments with the D2 receptor agonist,
quinpirole, produced similar results in both the VTA and
OB, indicating that this inhibition is specific to D2 receptors
(Hsia et al., 1999; Berkowicz and Trombley, 2000; Koga and
Momiyama, 2000; Ennis et al., 2001). DA also reduced the
frequency of spontaneous miniature EPSCs in VTA neurons
without affecting their mean amplitude, suggesting that the
inhibitory effects of DA are presynaptic (Koga and Momiyama,
2000).
Dopamine and GABA Co-release from
Midbrain Dopaminergic Neurons
Midbrain VTA and SNc DA neurons provide input onto
the striatum that is not strictly dopaminergic. Midbrain DA
neurons have been shown to co-release DA and GABA onto
medium spiny neurons of the striatum (Tritsch et al., 2012;
Borisovska et al., 2013; Chuhma et al., 2014; Vaaga et al., 2014).
This co-release produces a large GABAA current that inhibits
medium spiny neurons (Tritsch et al., 2012). Interestingly, these
dopaminergic neurons package GABA into vesicles via the
vesicular monoamine transporter 2, a traditional DA transporter,
and not by the vesicular GABA transporter (Tritsch et al., 2012).
Cholinergic interneurons in the NAcc core also receive a
heterogeneous input from the midbrain (Chuhma et al., 2014).
Those neurons receive dopaminergic and GABAergic input from
the midbrain DA neurons, causing hyperpolarization via the
D2 and GABAA receptors, respectively (Chuhma et al., 2014).
However, cholinergic interneurons in the NAcc medial shell
do not receive GABAergic input from midbrain dopaminergic
neurons (Chuhma et al., 2014). This heterogeneity of midbrain’s
dopaminergic input to the NAcc and dorsal striatum could
be involved with reward-related learning (Chuhma et al.,
2014).
Gap Junctions in the Midbrain’s
Dopaminergic and GABAergic Neurons
As with all other dopaminergic brain areas discussed in this
review, the midbrain is also rich in gap junctions (Stobbs et al.,
2004; Vandecasteele et al., 2005; Allison et al., 2006). Within
the VTA, GABA neurons are strongly coupled to each other
via Cx36 gap junctions (Stobbs et al., 2004), with an estimate
of 2,000 channels per cell (Allison et al., 2006). The presence
of Cx36 was confirmed with quantitative reverse transcription
polymerase chain reaction, immunohistochemistry, and by the
reduction of spiking after the application of the Cx36 specific
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 April 2017 | Volume 11 | Article 91
fncel-11-00091 March 30, 2017 Time: 13:59 # 10
Korshunov et al. Dopamine’s Role in Circadian Rhythms
blocker, mefloquine (Allison et al., 2006). It was suggested that
VTA GABA neurons, not VTA DA neurons, express Cx36
channels, due to the fact that GABA VTA neurons have a different
electrophysiological profile from DA neurons (Allison et al.,
2006). However, recent evidence may imply that these GABA
VTA neurons also express DA, because it was shown that VTA,
as well as SNc, projection neurons express both DA and GABA
(Tritsch et al., 2012; Chuhma et al., 2014). In the SNc of rat
pups, gap junctions are expressed differently during postnatal
development (Vandecasteele et al., 2005). For example, it was
found that 40% of neurons from rats aged between P5 and
P10 were coupled, that no neurons were coupled between the
ages of P10 and P15, and that 17% of neurons were coupled
between the ages of P10 and P15 (Vandecasteele et al., 2005). It
would be informative to test for Cx36 and vesicular monoamine
transporter 2 immunoreactivity in the VTA to confirm whether
VTA DA neurons also express Cx36 gap junctions and also
to observe how gap junction coupling changes later in rodent
development.
Parkinson’s Disease and the Midbrain
and Striatum
The degeneration of the dopaminergic neurons in the SNc
is the most well-known cause of motor symptoms in PD,
including bradykinesia (Carlsson, 1972). However, increasing
evidence suggests that midbrain DA loss in patients with PD
could lead to motor and non-motor circadian dysfunction. As
mentioned in the section “Introduction,” there are a number of
limitations to neurotoxin-based and transgenic animal models of
PD (see Fifel and Cooper, 2014). One exception is the transgenic
MitoPark Parkinsonian mouse, which has been shown to develop
progressive cellular and motor alterations analogous to those seen
in idiopathic PD, including a gradual loss of midbrain (e.g., VTA
and SN) dopaminergic neurons (Ekstrand et al., 2007; Galter
et al., 2010; Fifel and Cooper, 2014).
This MitoPark mouse was used to study the rest/wake
activities and locomotion throughout the progression of PD
in the mouse’s lifetime (Fifel and Cooper, 2014). To assess
daily rest and locomotor activity, as well as how lighting
could affect these activities, extensive entrainment periods
of light and dark conditions were used (Fifel and Cooper,
2014). These entrainment periods lasted for several weeks and
showed evidence of the age-related degeneration of dopaminergic
neurons with progression of the disease (Fifel and Cooper, 2014).
Prior to the onset of PD, 11-week-old MitoPark mice
entrained well to the 12-h:12-h light-dark cycle, and when
exposed to a 1 h light pulse and then released into constant
darkness, showed a phase delay of activity that was comparable
to that in their control counterparts (Fifel and Cooper, 2014).
However, by age 26 weeks, when DA levels in the nigrostriatal
regions of the MitoPark mouse have been shown to be decreased
(Galter et al., 2010), the locomotor activity of MitoPark mice
had become completely arrhythmic when the mice were
re-assessed under constant darkness (Fifel and Cooper, 2014).
MitoPark mice also lost circadian control of locomotor activity
when exposed to constant, bright light (Fifel and Cooper, 2014).
However, over the experiment’s duration, the daily rhythm
of rest/activity in a light-dark cycle in MitoPark mice was
maintained (Fifel and Cooper, 2014).
In addition to motor symptoms, PD is associated with non-
motor symptoms involving loss of midbrain DA. Patients with
PD often experience dysfunction of REM sleep (Chaudhuri and
Schapira, 2009), which appears to be regulated by dopaminergic
neurons in the SNc (Lima et al., 2007). In an MPTP rat model
of PD, a strong correlation was found between the number of
SNc DA neurons lost and the percentage decrease in REM sleep
(Lima et al., 2007). Patients with PD may develop RBD, which is
characterized by the enacting of dreams, often with flailing of the
limbs (Chaudhuri and Schapira, 2009; Videnovic and Golombek,
2013). RBD has been shown to be present in nearly 25–50% of
people with PD, and it is often a precursor to PD (Chaudhuri and
Schapira, 2009; Lima, 2013).
Degeneration of the dopaminergic neurons in the midbrain’s
SNc in patients with PD is also important to the striatum, as SNc
dopaminergic neurons project to the striatum via the nigrostriatal
pathway. TH, DA, and its metabolites, DOPAC and HVA, show
daily rhythms of expression in the striatum (Castañeda et al.,
2004; Webb et al., 2009), where DA regulates rhythms of clock
gene and protein expression (Imbesi et al., 2009; Hood et al., 2010;
Gravotta et al., 2011). In patients with PD, reduced DA input to
the striatum due to nigrostriatal degeneration could blunt daily
rhythms of clock gene expression and contribute to circadian
disruptions (Videnovic and Golombek, 2013; Verwey et al., 2016).
IPT-SPECT imaging data suggest that reduced striatal dopamine
transporters may contribute to the pathophysiology of RBD
(Eisensehr et al., 2003). Another sleep disorder found in patients
with PD is RLS, with a reported prevalence of 8–50% (Videnovic
and Golombek, 2013). Some imaging (PET) data support the
hypothesis that disturbed striatal dopamine transmission is
involved in the pathophysiology of RLS (Turjanski et al., 1999).
HYPOTHALAMUS
One site for DA’s unique, circadian-like neuromodulatory
activities is within the arcuate nucleus of the hypothalamus
(see Figure 4 in Freeman et al., 2000; Bertram et al., 2010).
There, DA regulates the daily rhythm of PRL, a hormone best
known for its involvement with milk production in mammals,
from the lactotrophs of the anterior pituitary gland (Freeman
et al., 2000; Bertram et al., 2010). An essential role of the
PRL rhythm is the maintenance of the corpus luteum and its
release of progesterone during pregnancy in rodents (Freeman
et al., 2000; Bertram et al., 2010). Therefore, DA also plays
a role in the regulation of reproductive mechanisms. There
are several DA neuronal subpopulations in the hypothalamus,
at least three of which contribute to the inhibition of PRL
release: TIDA, tuberohypophyseal dopamine neurons, and
periventricular hypophyseal dopamine neurons (Gerhold et al.,
2001). Additional data from this lab suggest that clock gene
expression, particularly Per1 and Per2, within TIDA neurons may
regulate the daily rhythmicity of DA release from these neurons
in ovariectomized rats (Sellix and Freeman, 2003; Sellix et al.,
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2006). This section focuses on the potential of TIDA neurons
to regulate the circadian rhythms of PRL release and potential
disruptions to PRL release in patients with PD. In regard to DA
receptors, the arcuate nucleus expresses D1 and D2 receptors
(Romero-Fernandez et al., 2014), and potentially D3 receptors on
TIDA neurons (Lin et al., 2000).
This section also discusses the role of DA in the SCN, the site of
the master clock. Interestingly, in one study, TH-positive neurons
were labeled within the SCN of neonatal hamsters (Strother et al.,
1998). The SCN expresses D1 and D5 receptors (Rivkees and
Lachowicz, 1997), where DA from other brain regions exerts
feedback effects (Mendoza and Challet, 2014). Finally, this section
reviews potential links between PD and the SCN, including mixed
results of animal studies implicating SCN involvement.
Dopamine from TIDA Neurons and the
Regulation of Prolactin Release
The TIDA neurons of the hypothalamus’ arcuate nucleus display
a rhythmic release of DA, which is out of phase with PRL release
(Freeman et al., 2000; see Figure 2 in Bertram et al., 2010).
In humans, PRL release is high in the nighttime and low in
the daytime, and DA release drops before the release of PRL
(Freeman et al., 2000; Bertram et al., 2010). Therefore, TIDA
DA release inhibits pituitary lactotrophs, decreasing PRL release
(Freeman et al., 2000; Bertram et al., 2010). However, PRL also
stimulates the activity of TIDA neurons, thereby increasing DA
release (Freeman et al., 2000; Bertram et al., 2010). These feedback
mechanisms can result from artificial cervical stimulation, which
results in PRL being released twice per day, at 300 and 1700 h,
and likely later in the day, while DA is released at around 1200 h
(Freeman et al., 2000; Bertram et al., 2010). This twice-daily and
daily release of PRL and DA, respectively, continues for a few
days without additional cervical stimulation, potentially showing
evidence of a circadian-like neuronal “memory” that drives the
expression of PRL days after stimulation (Freeman et al., 2000;
Helena et al., 2009; Bertram et al., 2010). It is thought that this
memory regulates the rhythms of DA and PRL (Freeman et al.,
2000; Helena et al., 2009; Bertram et al., 2010).
GABA release from Hypothalamic
Tuberoinfundibular Dopamine Neurons
Amongst other dopaminergic neuronal populations of the
arcuate nucleus, TIDA neurons appear to also release GABA
(Zhang and van den Pol, 2015). GABA release from the arcuate
nucleus may inhibit PRL release (McCann and Rettori, 1986) and
other neurons (including TIDA) of the arcuate nucleus, as well
(Zhang and van den Pol, 2015). By using optogenetics, Zhang
and van den Pol (2015) activated DA neurons of the arcuate
nucleus while recording from other arcuate neurons, both TIDA
and non-TIDA neurons. Recordings showed a large-amplitude,
inward (depolarizing) current with fast decay, followed by a
small-amplitude, outward (hyperpolarizing) current with slow
decay (Zhang and van den Pol, 2015). This outward current
was determined to be a GABAA current, since it was blocked
by the GABAA antagonist bicuculline (Zhang and van den
Pol, 2015). Therefore, TIDA neurons also release GABA, which
hyperpolarizes neurons in the arcuate nucleus, and, potentially,
the lactotrophs of the anterior pituitary (McCann and Rettori,
1986; Zhang and van den Pol, 2015). GABA release from
TIDA neurons onto other arcuate nucleus neurons may help to
keep hypothalamic DA activity low until 1200 h in cervically
stimulated rats (Helena et al., 2009), and it may contribute to the
circadian rhythmic activity in the hypothalamus.
SCN and Role of Dopamine
The SCN, located above the optic chiasm, maintains mammalian
circadian rhythms by being entrained by light it receives through
the retinohypothalamic tract and by entraining the rhythms
of peripheral regions. Within neurons of both the SCN and
periphery, 24-h oscillations are generated through a clock gene
transcriptional and translational feedback loop (Lowrey and
Takahashi, 2011). DA is relevant to the SCN, as the main SCN
clock communicates timing information with other brain clocks
to regulate DA activity, and DA also appears to have feedback
effects on the SCN (Mendoza and Challet, 2014).
A role for dopaminergic modulation of SCN-related circadian
rhythmicity is suggested by the presence of D1 and D5 receptors
in the SCN (Rivkees and Lachowicz, 1997). In fact, DA may be
necessary to entrain the developing, fetal SCN (Mendoza and
Challet, 2014). Prenatal exposure to the D1 receptor agonist,
SKF38393, disrupts the expression of c-fos (a marker of neuronal
activity) in the neonatal SCN (Ferguson et al., 2000). Light pulses
also mimic the effects of D1 receptor activation in neonatal
hamsters, suggesting that maternal DA represents daytime to the
fetal SCN (Viswanathan and Davis, 1997).
Recent evidence that methylphenidate alters the electrical
firing rate and clock gene expression in the SCN (Antle et al.,
2012; Baird et al., 2013; Mendoza and Challet, 2014) suggests that
some drug-induced changes in DA neurotransmission also may
influence SCN clock activity. Data from mostly animal models
of PD (see below), implicating dopamine in SCN dysfunction,
are mixed, but suggest that DA depletion may affect circadian
rhythm mechanisms differently in the SCN than in peripheral
hypothalamic areas.
Parkinson’s Disease and the
Hypothalamus
The proposed idea that PD is disruptive to circadian rhythms
would be central to the functioning of the hypothalamus,
where the SCN resides. Mechanisms underlying circadian
fluctuations in signs and symptoms in patients with PD remain
unclear, although altered DA metabolism and DA receptor
downregulation have been implicated (Videnovic and Golombek,
2013). Sites of disruption may be along afferent pathways to
the SCN (e.g., impaired light transmission due to dopaminergic
retinal degeneration), within the SCN itself (e.g., altered clock
gene expression), or within downstream peripheral efferent
pathways (e.g., altered output) (Videnovic and Golombek, 2013).
Data from mostly animal models implicating SCN dysfunction
in PD is mixed. Clock gene and protein expression in the SCN is
unaffected in some animal models of PD, but is affected in others.
For example, studies have shown that the photoresponse of the
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SCN is unaltered in D2 receptor knockout mice, but masking
(which could hide potential SCN dysfunction by exposing a
nocturnal animal to light) was abolished in these mice (Doi et al.,
2006). The expression of Per2 and PER2 in the SCN is unaffected
in some Parkinsonian animal models (Gravotta et al., 2011; Kudo
et al., 2011). In addition, the rhythmic release of melatonin
and cortisol (a function regulated by the SCN) is unaffected in
Parkinsonian non-human primates (Fifel and Cooper, 2014; Fifel
et al., 2014), which mirrors a finding that nighttime melatonin
release in PD patients was similar to that of control patients (Fertl
et al., 1993). While these findings suggest that the central rhythms
of the SCN are unaffected in some models and patients of PD,
other studies may contradict this notion.
The SCN of a Parkinsonian rat model (symptoms were
induced by rotenone administration) displayed increased levels
of expression of Per2 at some time points, varying levels of
expression of Cry2 at different time points, and reduced levels
of expression of Per1 and Bmal1 at some time points (Mattam
and Jagota, 2015). In addition, the daily pulse of Per1, Per2, Cry1,
Cry2, and Bmal1 was significantly decreased in the SCN of the
rotenone-induced PD rat model (Mattam and Jagota, 2015). In
a Parkinsonian mouse model (initiated by the administration of
MPTP), the levels of Bmal1, Cry1, Dec1, and Rev-erbα in the
SCN were significantly decreased at some time points (Hayashi
et al., 2013). The finding of normal PER2 expression in the SCN,
but altered electrical output from the SCN, in a Parkinsonian
(α-synuclein overexpressing) transgenic mouse further suggests
disordered function or synchrony in the SCN (Kudo et al., 2011;
Musiek, 2015). Therefore, the extent to which PD affects the SCN,
and through which mechanisms, remains unclear.
MTPT-treated mice also had significantly lower locomotor
activity during nocturnal hours and lower body temperatures
(implying the involvement of the hypothalamus) during
daytime and nighttime hours compared to the control
mice (Hayashi et al., 2013). Peripheral hypothalamic areas,
including the periventricular nucleus, demonstrate decreased
expression of PER2 after the depletion of DA neurons with
6-hydroxydopamine (Gravotta et al., 2011). This suggests that
DA depletion can affect circadian rhythm mechanisms differently
in the SCN than in peripheral hypothalamic areas.
Hypothalamic DA neurons are also affected in PD, as is
evidenced by both a 50% decrease in DA neurons in postmortem
brains of PD patients (Conte-Devolx et al., 1985) and a decrease
in DA levels of hypothalamic extracts from PD patients compared
with control subjects (Pique et al., 1985). A PET study also
showed a significant decrease in D2 receptor availability in
the hypothalami of PD patients compared to that in control
subjects (Politis et al., 2008). Hypothalamic DA degeneration
may be related to the progression of PD, but earlier stages of
the disease may not affect DA significantly. For example, plasma
PRL levels of patients with early stages of idiopathic PD were not
significantly different from the levels of the age-matched controls
(Aziz et al., 2011), implicating proper function of DA from
TIDA neurons. Conversely (and strange when considering that
DA reduction should increase PRL levels), other patients with
PD have shown significantly lower levels of plasma PRL (Murri
et al., 1980; Winkler et al., 2002). Yet again, other PD patients
have shown an increase in nocturnal PRL (Bellomo et al., 1991).
These results provide evidence that hypothalamic DA neurons
are affected with the progression of PD, with clear implications
to normal circadian rhythms and potential disruption of PRL
cycling. However, the exact mechanism as to how TIDA and other
hypothalamic DA neurons are affected by the progression of the
disease is not clear.
DISCUSSION
Circadian rhythms synchronize nearly every daily biological
process – from gene transcription to behavior – and evidence
of DA’s importance in the modulation of circadian rhythms
is becoming more apparent. DA has been shown to have
circadian-like activities in the retina, OB, striatum, midbrain,
and hypothalamus, where it regulates, and is regulated by,
clock genes in some of these areas. The various neuronal
and molecular mechanisms reviewed here, and the mounting
evidence that neurodegenerative diseases such as PD influence
circadian rhythms, show that DA has both direct and indirect
impacts on some of the circadian rhythms of the SCN and these
peripheral brain areas (see Supplementary Table 1).
Summary of Dopamine’s Involvement in
Parkinson’s Disease and Associated
Circadian Dysfunction
In addition to causing classic motor symptoms, reduced
midbrain DA has been shown to disrupt circadian control of
locomotor activity (Fifel and Cooper, 2014) and REM sleep
(Lima et al., 2007) in PD. Reduced DA in the striatum due to
nigrostriatal degeneration could contribute to RLS, blunt clock
gene expression, and disrupt circadian rhythms in patients with
PD (Turjanski et al., 1999; Videnovic and Golombek, 2013;
Verwey et al., 2016).
Reduced DA levels in the retina observed in patients with
PD (Nguyen-Legros, 1988; Harnois and Di Paolo, 1990; Adam
et al., 2013) may contribute to visual symptoms (see Archibald
et al., 2009) and impair light adaption (Prigge et al., 2016). As DA
modulation of ipRGCs is involved in photic entrainment of the
SCN (Gooley et al., 2001; Sakamoto et al., 2005), decreased retinal
DA levels associated with PD may disrupt circadian rhythms.
Patients with PD often experience early olfactory dysfunction
(Doty et al., 1988; Ross et al., 2008; Doty, 2012). Some olfactory
dysfunction is linked to pathology and increased TH and DA
levels in the OB (Del Tredici et al., 2002; Huisman et al., 2004;
Mundinano et al., 2011), which may impair odor detection (Doty
and Risser, 1989; Huisman et al., 2004) and odor discrimination
(Tillerson et al., 2006) via actions at D2 receptors (Doty and
Risser, 1989; Hsia et al., 1999; Berkowicz and Trombley, 2000;
Ennis et al., 2001; Davila et al., 2003).
Mechanisms underlying circadian disruptions in PD remain
unclear, but may involve afferent pathways to the SCN
(e.g., impaired light transmission due to dopaminergic retinal
degeneration) (Harnois and Di Paolo, 1990; Adam et al.,
2013), the SCN itself (e.g., altered clock gene expression)
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(Hayashi et al., 2013; Mattam and Jagota, 2015), or downstream
peripheral efferents (e.g., altered electrical output from the SCN)
(Kudo et al., 2011; Videnovic and Golombek, 2013; Musiek,
2015). DA from other brain regions may exert feedback effects
in the SCN via actions at D1 and D5 receptors (Rivkees and
Lachowicz, 1997; Mendoza and Challet, 2014). Patients with PD
have altered levels of PRL (Murri et al., 1980; Bellomo et al.,
1991; Winkler et al., 2002), suggesting disruptions in PRL cycling
involving TIDA neurons (Freeman et al., 2000; Bertram et al.,
2010).
New Directions in Research
New research should continue to explore how DA, as well as other
neurotransmitters, affect(s) the circadian rhythms of the retina,
OB, striatum, midbrain, and hypothalamus. Neurotransmitters
serotonin and norepinephrine should also be studied, since the
raphe nuclei and locus coeruleus neurons project throughout the
brain (including the rat OB; Shipley et al., 1985; McLean and
Shipley, 1987), and the activity of both transmitters fluctuates
between sleep and wake cycles (Nolte, 2009; Corthell et al., 2013).
Melatonin, a hormone that helps to induce sleep during darkness
and regulates the release of DA in the retina (Doyle et al., 2002a),
should continue to be studied in other brain areas to clarify how
it interacts or regulates the other neurotransmitters. In addition
to the brain areas discussed here, the circadian rhythms of other
brain areas also may be influenced by DA’s activity. For example,
the hippocampus receives a large dopaminergic input from the
VTA via the mesolimbic pathway, and this input may regulate
clock genes and proteins (McCarthy and Welsh, 2012), which
could be involved in hippocampus-dependent learning (Ito and
Schuman, 2007) and could protect against hippocampal cell death
(Bozzi et al., 2000; Rocha et al., 2012; Bozzi and Borrelli, 2013).
CONCLUSION
Circadian rhythms drive the daily biological processes, which in
turn drive our daily lives. Disruptions in circadian rhythms –
which can result from PD and other disorders as well as from
environmental influences – can lead to various health risks and
disorders (Schernhammer et al., 2006; Sookoian et al., 2007;
Dochi et al., 2009; Dominguez-Rodriguez et al., 2009; McHill
et al., 2014). As our understanding of how DA affects and is
affected by circadian rhythms grows, new diagnostic methods
(such as detection of hyposmia or anosmia as a precursor to
circadian disruption) and pharmacologic tools may be developed
to help those aﬄicted with disorders of circadian rhythms.
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